Fulcrum Therapeutics Plunges After FDA Secondary Malignancy Concerns Force Halt of Lead Sickle Cell Program Pociredir
Fulcrum Therapeutics plunged after halting its lead Pociredir program for sickle cell disease following FDA feedback
Read the full story on market.news
🇺🇸 United States Stocks Breaking biotech pharma healthcare analyst-downgrade
What is your take? Drop your thoughts below. 